Zeiss Meditec Braces for December Earnings Test as Barclays Turns Bearish
Published on 11/18/2026 at 17:21 | Editorial boerse-global.deBarclays has cut its rating on Carl Zeiss Meditec from "Equal Weight" to "Underweight" and trimmed its price target to 26 euros from 27 euros. The downgrade lands with the stock trading at 33.62 euros, down 0.7% on the day — still comfortably above the new target.
At the heart of the bearish call is analyst Jonathon Unwin's warning that adjusted EBITA could miss the consensus by 8% in the fourth fiscal quarter. That figure is a forecast, not a reported deviation, and the distinction matters: the negative scenario remains a prediction until the company publishes its numbers, expected on 10 December.
Unwin points to two separate drags. Ophthalmic Devices is running weak, while Microsurgery faces very high year-earlier comparatives. Neither is a single isolated problem, and investors will be watching whether the results confirm both reservations or show at least one to be less severe than feared.
A Sector Backdrop That Cuts Both Ways
The Barclays study, published yesterday, frames the call: even as earnings momentum across the European medtech sector has stabilized, Carl Zeiss Meditec ranks among the weaker-positioned companies in the field. A friendlier industry trend, in that view, would not by itself prove an improvement at the individual company level.
Should investors sell immediately? Or is it worth buying Carl Zeiss Meditec?
Broader risks complicate the picture further. Barclays analyst Hassan Al-Wakeel cites inflation, interest rates and US Section 232 tariffs as potential burdens on European medtech in 2027. Those are sector-wide headwinds rather than a quantified earnings forecast for Zeiss Meditec, but they limit how much weight a single stronger quarter can carry.
Guidance is unlikely to offer much clarity either. Unwin expects only directional statements for fiscal 2027. Should that hold, meeting the quarterly consensus would help — but would not, on its own, answer the question of where earnings go from here.
Cost Cuts and a China Approval
Alongside the analyst debate, the company is reshaping its cost base. Changes are planned at the Oberkochen site affecting employees in the mid-double-digit range, with talks with worker representatives still under way as of Friday and the measures not yet final. They form part of the "ProfitUp" savings program, under which roughly 600 to 700 positions are expected to go worldwide. Management aims to lift annual earnings by more than 200 million euros through the program by fiscal 2028/29.
On the product side, ZEISS Medical Technology reported in November that China's National Medical Products Administration had approved the PT LUNANA phakic intraocular lens. The product is intended to broaden the portfolio for treating myopia in China.
What Would Move the Narrative
The optimistic path does not require robust growth. A result closer to consensus than Unwin fears could undercut the basis for the pessimistic view — provided the business development does not fully confirm his reservations. Explanations around the two flagged divisions would carry particular weight: a milder-than-expected showing in Ophthalmic Devices would soften a central drag, and Microsurgery holding up better than feared despite tough comparatives would weaken the skeptical case on that front too. Both are possibilities, not visible improvements.
Carl Zeiss Meditec at a turning point? This analysis reveals what investors need to know now.
The opposite outcome — confirmation of the expected shortfall paired with continued weakness in Ophthalmic Devices — would leave the burden unexplained by demanding prior-year figures alone, and the question of operational resilience would linger. A smaller gap would blunt Unwin's skepticism without demonstrating a full operational turnaround.
For now, the December figures are the next concrete checkpoint. The earnings number itself is only part of it; just as important is whether management's commentary opens a credible perspective beyond the quarter.
Ad
Carl Zeiss Meditec Stock: New Analysis - 18 November
Fresh Carl Zeiss Meditec information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
